Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy | MicrobiomeTrials← Back to trialsNCT02362438
Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy
CompletedPHASE1INTERVENTIONAL
Trial Details
Start: 2015-04-24Est. Completion: 2026-04-10
Enrollment target: 14 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Giant Axonal Neuropathy (GAN)
Giant axonal neuropathy (GAN) is a rare pediatric disorder caused by autosomal recessive mutations in the GAN gene. GAN …
Dallas, United StatesEst. completion Dec 31, 2031
Giant Axonal Neuropathy
Giant Axonal Neuropathy (GAN) is a devastating and rare childhood disease. Children with GAN develop increasing muscle w…
New York, United StatesCompleted Dec 2014